Ocera Therapeutics
Ocera Therapeutics sponsors 9 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 7 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Mild Hepatic Encephalopathy, with 1 trials.
Trial Pipeline
9 total, page 1 of 1
OCR002-SP103 - Oral Immediate Release Study
NCT03846843
Phase 2B Efficacy/Safety of Ornithine Phenylacetate in Hospitalized Cirrhotic Patients With Hepatic Encephalopathy (STOP-HE)
NCT01966419
AST-120 Used to Treat Mild Hepatic Encephalopathy
NCT00867698
Safety and Efficacy of AST-120 in Patients With GERD Who Continue to be Symptomatic on a Standard Dose of PPI
NCT00587275
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy
NCT00558038
Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome
NCT00583128
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
NCT00583531
Safety and Efficacy of AST-120 in the Treatment of Pouchitis
NCT00583076
Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas
NCT00321412
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 7 |
| Phase 3 | 1 |
Therapeutic Areas
What the Pipeline for Ocera Therapeutics Shows
According to the ClinicalTrials.gov registry, Ocera Therapeutics is linked to 9 US clinical trials across every stage of research activity. Of those, 0 studies are currently recruiting, about 0% of the sponsor's indexed portfolio, and 7 are already marked complete, representing roughly 78% of the total.
The phase mix for Ocera Therapeutics reports 1 late-stage studies (Phase 3 and Phase 4 combined) and 8 earlier-phase studies (Phase 1 and Phase 2).
The top therapeutic focus area indexed for Ocera Therapeutics is Mild Hepatic Encephalopathy with 1 linked trial, and 0 other condition areas appear in the top list above.
How to read these pipeline numbers
Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work, safety, dosing, and early signal detection, and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice, verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.